- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07393126
Auswirkungen des Verzehrs des Testprodukts auf das Urinieren bei gesunden japanischen Erwachsenen
Auswirkungen des Konsums des Testprodukts auf das Urinieren bei gesunden japanischen Erwachsenen: Eine randomisierte, placebokontrollierte, doppelblinde, parallele Gruppenvergleichsstudie
The goal of this clinical trial is to test in Japanese adults who experience concerns regarding urinary frequency. The main question it aims to answer is:
•Does consumption of Cranberry Phospholipids reduce daytime urinary frequency?
Participants will be given the following tasks:
- Take two tablets daily containing Cranberry Phospholipid for eight weeks.
- Answer the questionnaire on the overactive bladder (OAB)-specific quality of life (QOL).
- Answer the questionnaire on OAB symptoms.
- Answer the questionnaire on urinary frequency during the study period. Researchers will compare Cranberry Phospholipids and placebo groups to see if Cranberry Phospholipids reduces daytime urinary frequency.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Naoko Suzuki
- Telefonnummer: +81-3-3818-0610
- E-Mail: group_gakujutsu@orthomedico.jp
Studieren Sie die Kontaktsicherung
- Name: Asami Baba, PhD
- Telefonnummer: +81-3-3818-0610
- E-Mail: asami-baba@orthomedico.jp
Studienorte
-
-
Tokyo
-
Nerima-ku, Tokyo, Japan, 176-0002
- Rekrutierung
- Nerima Medical Association Minami-machi Clinic
-
Kontakt:
- Naoko Suzuki
- Telefonnummer: +81-3-3818-0610
- E-Mail: group_gakujutsu@orthomedico.jp
-
Kontakt:
- Asami Baba, PhD
- Telefonnummer: +81-3-3818-0610
- E-Mail: asami-baba@orthomedico.jp
-
Hauptermittler:
- Masafumi Nagata, MD
-
Shinagawa-Ku, Tokyo, Japan, 141-0022
- Rekrutierung
- Medical Corporation Seishinkai, Takara Clinic
-
Kontakt:
- Naoko Suzuki
- Telefonnummer: +81-3-3818-0610
- E-Mail: group_gakujutsu@orthomedico.jp
-
Kontakt:
- Asami Baba, PhD
- Telefonnummer: +81-3-3818-0610
- E-Mail: asami-baba@orthomedico.jp
-
Hauptermittler:
- Tsuyoshi Takara, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Japanese
- Men or women
- Adults
- Healthy individuals
- Individuals with positive urine leukocytes at baseline
- Individuals whose score of urinary urgency of overactive bladder symptom score (OABSS) is less than two or total score of OABSS is less than three at baseline
- Individuals whose "frequent urination during the daytime hours" of "symptom bother" of OAB-q is relatively high at baseline
Exclusion Criteria:
- Individuals undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction
- Individuals carrying a pacemaker or an implantable cardioverter defibrillator
- Individuals undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
- Individuals who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily diet
- Individuals currently regularly taking medications (including herbal medicines) and supplements
- Individuals who are allergic to medicines and/or the test-product-related products in this trial
- Individuals with urinary pain
- Individuals undergoing treatment, have had treatment within two months, or need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, prostatitis, prostate cancer, overactive bladder, hypoactive bladder, cystitis, interstitial cystitis, bladder cancer, bladder stones, urethritis, urethral stricture, neurological disease, polyuria, and nocturnal polyuria
- Individuals have overactive bladder symptom (individuals who urinate eight times or more per day, and have urinary urgency at least once a week)
- Individuals wake up twice or more to urinate at bedtime
- Individuals are pregnant, breast-feeding, and planning to become pregnant
- Individuals have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
- Individuals are judged as ineligible to participate in the trial by the physician
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Cranberry Phospholipids
Take two tablets (containing 120 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
|
Placebo-Komparator: Placebo
Take two tablets (containing 0 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Measured value for the Overactive Bladder Questionnaire (OAB-q) questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Zeitfenster: After the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific quality of life (QOL). The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
After the 8-week intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Individuals whose the response to the OAB-q questionnaire item "frequent urination during the daytime hours" improved by one or more scale points after the 8-week intervention compared to Baseline
Zeitfenster: Baseline, and after the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, and after the 8-week intervention
|
|
The amount of change, and percentage of change from Baseline for the OAB-q questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Zeitfenster: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, amount of changes, and percentage of changes from Baseline for all other questionnaire items of the OAB-q, excluding "frequent urination during the daytime hours," after the 8-week intervention
Zeitfenster: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, and amount of changes and percentage of changes from Period 1 for the average frequency of urination during the daytime, during the nighttime, and all day, as measured during Periods 2 to 9
Zeitfenster: Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
Participants will maintain a daily diary of their urination frequency during two distinct periods: for 7 days immediately preceding the Baseline, and from the beginning of the intervention until the day before the final examination. |
Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
|
Individuals who experienced adverse events
Zeitfenster: After the 8-week intervention
|
During the trial period, if a participant exhibits any clinically significant "new manifestation of abnormality" or "aggravation" in his/her physical signs and symptoms, it is considered to be an adverse event. |
After the 8-week intervention
|
|
Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Baseline
Zeitfenster: Baseline, and after the 8-week intervention
|
The ratio of cases which had test items stated in urinalysis and peripheral blood examination within their respective standard ranges before intervention but exceeded the ranges after intervention are calculated, intergroup comparison at each time point is performed using tests for comparing proportions. |
Baseline, and after the 8-week intervention
|
|
Body height
Zeitfenster: Baseline, and after the 8-week intervention
|
Body height is measured using a height meter. |
Baseline, and after the 8-week intervention
|
|
Body weight
Zeitfenster: Baseline, and after the 8-week intervention
|
Body weight is measured using a body scale. |
Baseline, and after the 8-week intervention
|
|
Blood pressure
Zeitfenster: Baseline, and after the 8-week intervention
|
Systolic and diastolic blood pressure are measured using a digital wrist-type sphygmomanometer. |
Baseline, and after the 8-week intervention
|
|
Urinalysis
Zeitfenster: Baseline, and after the 8-week intervention
|
A urine sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
|
Peripheral blood examination
Zeitfenster: Baseline, and after the 8-week intervention
|
A venous blood sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 01170-0018-29
- UMIN000060011 (Registrierungskennung: UMIN-CTR)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data sharing will be discussed among the research affiliates after the study is completed.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .